Italy DNA Vaccine Market Size, Share & Trends Analysis Report by Type (Animal DNA Vaccine, Human DNA Vaccine) By Technology (Plasmid DNA Vaccine and Plasmid DNA Delivery) By Application (Oncology, Infectious Disease, and Others) Forecast period (2019-2025).
Italy DNA Vaccine market is anticipated to grow at a CAGR 41.3% during the forecast period. Most of Italy’s economy is driven by manufacturers of high-quality consumer goods produced by small and medium-sized enterprises. Similar to the UK and Germany the surviving infant rate in Italy is almost 100%. In 2017, the surviving infant rate was 484 out of 485. The major disease reported in the country is measles, rubella and tetanus. As per WHO, in 2017 the reported cases of the measles, mumps, pertussis were 4,050,508 and 510 respectively. No certain cases were reported for the following diseases from 2013 to 2016 expect measles. As per WHO, the major vaccinations scheduled in the country were aP, Diphtheria, DTaP, HepA, HepB, and Rotavirus. The government of Italy has made 12 vaccines mandatory for the children in May 2017. The mandatory vaccines include polio, diphtheria, tetanus, hepatitis B, Haemophilus influenzae B, meningitis B, meningitis C, measles, mumps, rubella, whooping cough and chickenpox.
Italy is a significant contributor to the Gavi Alliance since 2006. The country is focusing on health system strengthening, newborn and child health, along with communicable and non-communicable diseases, and mental health. The market is segmented on the basis of type, application, and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on application, the market is segmented into oncology, infectious disease and others. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery.
The key market players that are active in the market include Eli Lilly and Co., GE Healthcare, GlaxoSmithKline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the Italy DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Italy DNA Vaccine Market Research and Analysis by Type
2. Italy DNA Vaccine Market Research and Analysis by Technology
3. Italy DNA Vaccine Market Research and Analysis by Application
The Report Covers:
Italy DNA Vaccine market is anticipated to grow at a CAGR 41.3% during the forecast period. Most of Italy’s economy is driven by manufacturers of high-quality consumer goods produced by small and medium-sized enterprises. Similar to the UK and Germany the surviving infant rate in Italy is almost 100%. In 2017, the surviving infant rate was 484 out of 485. The major disease reported in the country is measles, rubella and tetanus. As per WHO, in 2017 the reported cases of the measles, mumps, pertussis were 4,050,508 and 510 respectively. No certain cases were reported for the following diseases from 2013 to 2016 expect measles. As per WHO, the major vaccinations scheduled in the country were aP, Diphtheria, DTaP, HepA, HepB, and Rotavirus. The government of Italy has made 12 vaccines mandatory for the children in May 2017. The mandatory vaccines include polio, diphtheria, tetanus, hepatitis B, Haemophilus influenzae B, meningitis B, meningitis C, measles, mumps, rubella, whooping cough and chickenpox.
Italy is a significant contributor to the Gavi Alliance since 2006. The country is focusing on health system strengthening, newborn and child health, along with communicable and non-communicable diseases, and mental health. The market is segmented on the basis of type, application, and technology. Based on type, the market is segmented into animal DNA vaccine and human DNA vaccine. Based on application, the market is segmented into oncology, infectious disease and others. Based on technology, the market is segmented into plasmid DNA vaccine and plasmid DNA delivery.
The key market players that are active in the market include Eli Lilly and Co., GE Healthcare, GlaxoSmithKline PLC., Inovio Pharmaceuticals Inc., Merck & Co., Novartis AG, Pfizer Inc., Roche Diagnostics GMBH and Sanofi Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups and technological advancements to stay competitive in the market.
Research Methodology:
The market study of the Italy DNA Vaccine market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The research team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.
Secondary Sources Include:
- Financial reports of companies involved in the market.
- Whitepapers, research-papers, and news blogs.
- Company websites and their product catalog.
The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation:
1. Italy DNA Vaccine Market Research and Analysis by Type
2. Italy DNA Vaccine Market Research and Analysis by Technology
3. Italy DNA Vaccine Market Research and Analysis by Application
The Report Covers:
- Comprehensive Research Methodology of the Italy DNA Vaccine market.
- This report also includes a detailed and extensive market overview with key analyst insights.
- An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
- Analysis of regional regulations and other government policies impacting the Italy DNA Vaccine market.
- Insights about market determinants which are stimulating the Italy DNA Vaccine market.
- Detailed and extensive market segments with regional distribution of forecasted revenues.
- Extensive profiles and recent developments of market players.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Eli Lilly and Co.
- GE Healthcare
- Glaxosmithkline PLC.
- Inovio Pharmaceuticals Inc.
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Roche Diagnostics GMBH
- Sanofi Inc.
